Ferric carboxymaltose IV

Phase 3Small molecule

AAssistance Publique - Hôpitaux de Paris

Ferric carboxymaltose IV is one of 11 small molecule programs targeting Scoliosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ScoliosisRecruiting

ScoliosisPhase 3

Recruiting

Competition

Competitive Landscape

14 competitors in Scoliosis

#DrugCompanyPhaseTrials

Cyklokapron

JJ Molner

Approved

2 2

MS Contin

HHikma Pharmaceuticals LLC

Approved

2 3

Marcaine

IInnocoll

Approved

1 4

Spravato

WWim Janssens

Approved

1 5

Cleviprex

Catapres

Ferric carboxymaltose IV

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 8

Anerem

AAcacia Pharma Ltd

Preclinical

1 9

Plasmalyte

SSeoul National University Hospital

Preclinical

1 10

Desmopressin Acetate

Teva

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2/3Recruiting

Scoliosis

NCT07217873

Q4 2028

ApprovedRecruiting

Postpartum Depression (PPD)

NCT06833788

Clinical

Trials by Indication[1]

Scoliosis1 trial

IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study

Recruiting·—·Phase 2/3·NCT07217873·120 enrolled

Postpartum Depression (PPD)1 trial

Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum Depression: a Multicentric Randomized Open-labelled Controlled Trial

Recruiting·AAssistance Publique - Hôpitaux de Paris·Approved·NCT06833788·2,860 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ferric carboxymaltose IV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ferric carboxymaltose IV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ferric carboxymaltose IV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

Ferric carboxymaltose IV

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Trials by Indication[1]

Scoliosis1 trial

Postpartum Depression (PPD)1 trial

References

Drug Info

Quick Facts

Related News